These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 29411181)

  • 1. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
    El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H
    Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region.
    Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L
    Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
    Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
    Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars in pediatric rheumatology and their introduction into routine care.
    Aragon Cuevas O; Hedrich CM
    Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
    Schulze-Koops H; Skapenko A
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
    Azevedo VF; Babini A; Caballero-Uribe CV; Castañeda-Hernández G; Borlenghi C; Jones HE
    J Clin Rheumatol; 2019 Mar; 25(2):91-100. PubMed ID: 30059414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Position paper from the Spanish Society of Rheumatology on biosimilar drugs.
    Abad Hernández MÁ; Andreu JL; Caracuel Ruiz MÁ; Belmonte Serrano MÁ; Díaz-González F; Moreno Muelas JV
    Reumatol Clin; 2015; 11(5):269-78. PubMed ID: 25982595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in rheumatology.
    Araújo FC; Gonçalves J; Fonseca JE
    Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars in rheumatology: understanding the rigor of their development.
    Goel N; Chance K
    Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential for biosimilars in rheumatology in Africa.
    Abu-Zaid MH; Adebajo A; El Miedany Y
    Ann Rheum Dis; 2023 Dec; 82(12):1508-1510. PubMed ID: 37468221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Biosimilars in the Middle East: Review Article.
    Jassim NA; Humadi YA
    Curr Rheumatol Rep; 2018 Jun; 20(7):45. PubMed ID: 29900477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The changing landscape of biosimilars in rheumatology.
    Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR
    Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars.
    Rezk MF; Pieper B
    Adv Ther; 2018 Jun; 35(6):749-753. PubMed ID: 29873005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).
    Schaeverbeke T; Pham T; Richez C; Wendling D
    Joint Bone Spine; 2018 Jul; 85(4):399-402. PubMed ID: 29574143
    [No Abstract]   [Full Text] [Related]  

  • 15. The advent of biosimilar therapies in rheumatology--"O brave new world".
    Scheinberg MA; Kay J
    Nat Rev Rheumatol; 2012 Jun; 8(7):430-6. PubMed ID: 22664834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biosimilars in rheumatology. Development and results of clinical trials].
    Alten R
    Z Rheumatol; 2015 Oct; 74(8):682-8. PubMed ID: 26347121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.
    Uhlig T; Goll GL
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv49-iv62. PubMed ID: 28903542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare professionals' perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study.
    Aladul MI; Fitzpatrick RW; Chapman SR
    BMJ Open; 2018 Nov; 8(11):e023603. PubMed ID: 30455389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current state of biosimilars in Mexico: The position of the Mexican College of Rheumatology, 2016.
    Xibille D; Carrillo S; Huerta-Sil G; Hernández R; Limón L; Olvera-Soto G; Jara-Quezada LJ; Esquivel A; Pérez-Rodríguez M
    Reumatol Clin (Engl Ed); 2018; 14(3):127-136. PubMed ID: 28807650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheumatology: biosimilars are here to stay.
    Hetland ML
    Rheumatology (Oxford); 2022 Apr; 61(4):1312-1313. PubMed ID: 34559204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.